drugset
drugset / Trial / NCT04811131

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

NCT04811131 ↗

Phase 2 Terminated 114 enrolled Arcutis Biotherapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the safety and efficacy of ARQ-252 cream in combination with NB-UVB phototherapy treatment in individuals with non-segmental facial vitiligo.

Timeline

Start
2021-03-04
Primary completion
2021-08-09
Completion
2021-08-09

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Drugs

EvaluationDrugModalityDoseRoute
Comparator ARQ-252 Unknown 0.3 % —

Indications

vitiligo